Dopaminergic foundations of schizotypy as measured by the German version of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE)—a suitable endophenotype of schizophrenia

The concept of schizotypy or “psychosis proneness” captures individual differences in perceptual, cognitive, and affective experiences that may relate to a range of psychotic disorders. The concept is an important way to assess the contribution of pre-existing psychological and genetically based biological features to the development of illnesses such as schizophrenia (so called endophenotypes). The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) is a widely used multi-dimensional measure of the construct and consists of four scales which mirror several groups of psychotic symptoms: Unusual Experiences (UnEx; positive symptoms), Cognitive Disorganization (CogDis; cognitive symptoms), Introvertive Anhedonia (IntAn; negative symptoms), and Impulsive Nonconformity (ImpNon; impulsive and antisocial symptoms). For the purpose of evaluating the suitability of schizotypy as an endophenotype of schizophrenia the current version of the O-LIFE was translated into German: its psychometric properties (including re-test reliability and construct validity) were examined in a large sample (n > 1200) and compared to those of the English original. The German version was both highly reliable and consistent with the original. The study aimed to show that schizotypy as measured by the O-LIFE can indeed be regarded as an endophenotype of schizophrenia in terms of genetic associations regarding relevant dopamine-related candidate polymorphisms of schizotypy [i.e., Val158Met-polymorphism of the COMT gene, uVNTR of the MAOA gene, Taq1A-polymorphism of the DRD2 gene, VNTR of the SLC6A3 (DAT) gene]. We also wanted to compare the genetic associations of the O-LIFE to those published using other operationalizations of schizotypy. Our results show a large number of significant associations and borderline-significant trends between the O-LIFE sub-scales and a range of genes, thereby supporting using the O-LIFE in the search for endophenotypic markers.

[1]  S. Radó.  Dynamics and classification of disordered behavior. , 1953, The American journal of psychiatry.

[2]  P. Meehl.  Schizotaxia, Schizotypy, Schizophrenia , 1962 .

[3]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[4]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[5]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[6]  T. Shippey.  The Road to Middle-Earth , 1982 .

[7]  A. Raine.  The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. , 1991, Schizophrenia bulletin.

[8]  X Li,et al.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.

[9]  Mike C. Jackson,et al.  New scales for the assessment of schizotypy , 1995 .

[10]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[11]  Gordon Claridge,et al.  Schizotypy: Implications for Illness and Health , 2002 .

[12]  Gordon Claridge,et al.  Theoretical background and issues , 1997 .

[13]  J. Smythies.  Oxidative reactions and schizophrenia: A review-discussion , 1997, Schizophrenia Research.

[14]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[15]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[16]  M. Nöthen,et al.  Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. , 1999, Human molecular genetics.

[17]  T. B. Ustün.  The global burden of mental disorders. , 1999, American journal of public health.

[18]  D. Comings,et al.  Molecular heterosis: a review. , 2000, Molecular genetics and metabolism.

[19]  T. Shippey.  J. R. R. Tolkien: Author of the Century , 2000 .

[20]  Philip D. Harvey,et al.  Cognition in schizophrenia : impairments, importance, and treatment strategies , 2000 .

[21]  C. Stefanis,et al.  Higher scores of self reported schizotypy in healthy young males carrying the COMT high activity allele , 2002, Molecular Psychiatry.

[22]  J. Hauser,et al.  [Lack of association between VNTR polymorphism of DAT gene and schizophrenia]. , 2002, Psychiatria polska.

[23]  A. Caspi,et al.  Role of Genotype in the Cycle of Violence in Maltreated Children , 2002, Science.

[24]  A. Nieoullon.  Dopamine and the regulation of cognition and attention , 2002, Progress in Neurobiology.

[25]  R. Murray,et al.  A quantitative genetic analysis of schizotypal personality traits , 2003, Psychological Medicine.

[26]  J. Addington,et al.  Cognitive functioning in first episode psychosis: initial presentation , 2003, Schizophrenia Research.

[27]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[28]  M Kurachi,et al.  Morphological brain changes associated with Schneider's first-rank symptoms in schizophrenia: an MRI study , 2004, Psychological Medicine.

[29]  O. Mason,et al.  Short scales for measuring schizotypy , 2005, Schizophrenia Research.

[30]  Martin Reuter,et al.  Association of the functional catechol-O-methyltransferase VAL158MET polymorphism with the personality trait of extraversion , 2005, Neuroreport.

[31]  D. Nettle.  Schizotypy and mental health amongst poets, visual artists, and mathematicians , 2006 .

[32]  M. Reuter,et al.  Imaging gene–substance interactions: The effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward , 2006, Neuroscience Letters.

[33]  Ulrich Ettinger,et al.  Schizotypy, attention deficit hyperactivity disorder, and dopamine genes , 2006, Psychiatry and clinical neurosciences.

[34]  O. Mason,et al.  The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE): Further description and extended norms , 2006, Schizophrenia Research.

[35]  R. Murray,et al.  A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population , 2007, Psychiatry Research.

[36]  S. Ryu,et al.  Association between Monoamine Oxidase A Polymorphisms and Anger-Related Personality Traits in Korean Women , 2007, Neuropsychobiology.

[37]  M. Reuter,et al.  Genetically Determined Differences in Learning from Errors , 2007, Science.

[38]  M. Leboyer,et al.  Schizotypal dimensions: An intermediate phenotype associated with the COMT high activity allele , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[39]  C. Stefanis,et al.  Effect of Schizotypy on Cognitive Performance and Its Tuning by COMT val 158 Met Genotype Variations in a Large Population of Young Men , 2007, Biological Psychiatry.

[40]  Mark Batey,et al.  The relationship between measures of creativity and schizotypy , 2008 .

[41]  Larry J Seidman,et al.  Premorbid IQ in schizophrenia: a meta-analytic review. , 2008, The American journal of psychiatry.

[42]  V Markov,et al.  Effect of COMT val158met genotype on cognition and personality , 2008, European Psychiatry.

[43]  M. Reuter,et al.  Response to Comment on "Genetically Determined Differences in Learning from Errors" , 2008, Science.

[44]  John P A Ioannidis,et al.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database , 2008, Nature Genetics.

[45]  Andrew Skol,et al.  Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. , 2009, Experimental and clinical psychopharmacology.

[46]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[47]  J. Smythies.  The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion , 1999, Neurotoxicity Research.

[48]  Muriel Walshe,et al.  Epistasis between the DAT 3′ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia , 2009, Proceedings of the National Academy of Sciences.

[49]  D. Collier,et al.  Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. , 2009, The American journal of psychiatry.

[50]  Jim van Os,et al.  The environment and schizophrenia , 2010, Nature.

[51]  K. Lesch,et al.  Variation in genes involved in dopamine clearance influence the startle response in older adults , 2011, Journal of Neural Transmission.

[52]  M. Large,et al.  Violence in first-episode psychosis: A systematic review and meta-analysis , 2011, Schizophrenia Research.

[53]  S. Javali,et al.  Effect Of Varying Sample Size In Estimation Of Reliability Coefficients Of Internal Consistency , 2011 .

[54]  C. Wellman,et al.  Social Deficits and Perseverative Behaviors, but not Overt Aggression, in MAO-A Hypomorphic Mice , 2011, Neuropsychopharmacology.

[55]  Qinghui Yu.  Developmental Monoamine Signaling Impacts Adult Affective and Aggressive Behaviors , 2012 .

[56]  P. Tata,et al.  The Rust Inventory of Schizotypal Cognitions RISC , 2022 .